share_log

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Director Ra Capital Management, L.P. Purchases 3,389,500 Shares

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Director Ra Capital Management, L.P. Purchases 3,389,500 Shares

Acrivon Therapeutics, Inc.（纳斯达克股票代码：ACRV）董事拉资本管理有限责任公司购买了3,389,500股股票
Defense World ·  2022/11/22 17:21

Acrivon Therapeutics, Inc. (NASDAQ:ACRV – Get Rating) Director Ra Capital Management, L.P. acquired 3,389,500 shares of the company's stock in a transaction dated Thursday, November 17th. The shares were bought at an average price of $12.50 per share, for a total transaction of $42,368,750.00. Following the purchase, the director now owns 4,384,206 shares in the company, valued at $54,802,575. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Acrivon Therapeutics, Inc.（纳斯达克股票代码：ACRV — 获取评级）董事Ra Capital Management, L.P. 在11月17日星期四的一笔交易中收购了该公司3,389,500股股票。这些股票的平均价格为每股12.50美元，总交易额为42,368,750.00美元。收购后，该董事现在拥有该公司的4,384,206股股份，价值54,802,575美元。该交易是在向美国证券交易委员会提交的文件中披露的，该文件可在 这个链接。

Acrivon Therapeutics Price Performance

Acrivon Therapeutics 价格

Shares of Acrivon Therapeutics stock opened at $12.51 on Tuesday. Acrivon Therapeutics, Inc. has a 12-month low of $12.50 and a 12-month high of $20.70.

周二，Acrivon Therapeutics的股票开盘价为12.51美元。Acrivon Therapeutics, Inc.创下12个月低点12.50美元，12个月高点为20.70美元。

Get
获取
Acrivon Therapeutics
Acrivon Therapeu
alerts:
警报：

About Acrivon Therapeutics

关于 Acrivon Therapeut

(Get Rating)

（获取评分）

Acrivon Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops precision oncology medicines. The company's lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1/2 for use in the treatment of platinum-resistant ovarian cancer; endometrial and bladder cancer; and SCCs, including SCCHN, cervical, and anal cancer.
Acrivon Therapeutics, Inc是一家临床阶段的生物制药公司，开发精准肿瘤药物。该公司的主要临床候选药物是 ACR-368，这是一种靶向 CHK1/2 的选择性小分子抑制剂，用于治疗耐铂卵巢癌；子宫内膜癌和膀胱癌；以及 sccs，包括 SCCHN、宫颈癌和肛门癌。

See Also

另见

  • Get a free copy of the StockNews.com research report on Acrivon Therapeutics (ACRV)
  • Three Ways To Win The Online Gambling Industry
  • Santa Claus Rally? Here's What Needs to Happen
  • Will the Return of Bob Iger Return the Magic to Disney Stock?
  • Is Ardelyx is A Buy After Slip in Early 2022
  • Is Tesla A Bargain Now As It Trades At Two-Year Lows?
  • 免费获取 StockNews.com 关于 Acrivon Therapeutics (ACRV) 的研究报告
  • 赢得在线赌博业的三种方法
  • 圣诞老人拉力赛？这是需要发生的事情
  • 鲍勃·艾格的回归会将魔法带回迪士尼股票吗？
  • Ardelyx 是 2022 年初一次又一次的下跌吗
  • 特斯拉现在是便宜货吗，因为它的交易价格处于两年低点？

Receive News & Ratings for Acrivon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

接收 Acrivon Therapeutics 每日的新闻和评级 -在下面输入您的电子邮件地址，通过Marketbeat.com的免费每日电子邮件时事通讯接收Acrivon Therapeutics及相关公司的最新新闻和分析师评级的简明每日摘要。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发